参考文献/References:
[1] Steele JC,Richardson JC,Olszewski J.Progressive supranuclear palsy.A heterogeneous degeneration Involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia[J].Arch Neurol,1964,10: 333-359.
[2] Barer Y,Chodick G,Cohen R,et al.Epidemiology of progressive supranuclear palsy:real world data from the second largest health plan in Israel[J].Brain Sci,2022,12(9).
[3] Takigawa H,Kitayama M,Wada-Isoe K,et al.Prevalence of progressive supranuclear palsy in Yonago:change throughout a decade[J].Brain Behav,2016,6(12):e00557.
[4] Krzosek P,Madetko N,Migda A,et al.Differential diagnosis of rare subtypes of progressive supranuclear palsy and PSP-Like syndromes-infrequent manifestations of the most common form of atypical parkinsonism[J].Front Aging Neurosci,2022,14:804385.
[5] Hglinger GU,Respondek G,Stamelou M,et al.Clinical diagnosis of progressive supranuclear palsy:the movement disorder society criteria[J].Mov Disord,2017,32(6):853-864.
[6] Stamelou M,Quinn NP,Bhatia KP."Atypical" atypical parkinsonism:new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide[J].Mov Disord,2013,28(9):1184-1199.
[7] Picillo M,Cuoco S,Tepedino MF,et al.Motor, cognitive and behavioral differences in MDS PSP phenotypes[J].J Neurol,2019,266(7):1727-1735.
[8] Karimi N,Bayram atak F,Arslan E,et al.Tau immunotherapy in Alzheimers disease and progressive supranuclear palsy[J].Int Immunopharmacol,2022,113(Pt B):109445.
[9] Matsuoka K,Takado Y,Tagai KJ,et al.Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy[J].J Neurol Sci,2023,444:120514.
[10]Respondek G,Kurz C,Arzberger T,et al.Which ante mortem clinical features predict progressive supranuclear palsy pathology?[J].Mov Disord,2017,32(7):995-1005.
[11]Respondek G,Stamelou M,Kurz C,et al.The phenotypic spectrum of progressive supranuclear palsy:a retrospective multicenter study of 100 definite cases[J].Mov Disord,2014,29(14):1758-1766.
[12]Kwasny MJ,Oleske DM,Zamudio J,et al.Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy[J].Front Neurol,2021,12:637176.
[13]Viscidi E,Litvan I,Dam T,et al.Clinical features of patients with progressive supranuclear palsy in an US insurance claims database[J].Front Neurol,2021,12:571800.
[14]Grimm MJ,Respondek G,Stamelou M,et al.How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy[J].Mov Disord,2019,34(8):1228-1232.
[15]Kim MK,Lee D,Yang X,et al.Saw-tooth vertical saccades in progressive supranuclear palsy[J].J Neurol,2023,270(7):3644-3646.
[16]Batla A,Nehru R,Vijay T.Vertical wrinkling of the forehead or procerus sign in progressive supranuclear palsy[J].J Neurol Sci,2010,298(1/2):148-149.
[17]Dix MR,Harrison MJ,Lewis PD.Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome). A report of 9 cases with particular reference to the mechanism of the oculomotor disorder[J].J Neurol Sci,1971,13(3):237-256.
[18]Litvan I,Mangone CA,McKee A,et al.Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival:a clinicopathological study[J].J Neurol Neurosurg Psychiatry,1996,60(6):615-620.
[19]Richardson JC,Steele J,Olszewski J.Supranuclear ophthalmoplegia,pseudobulbar palsy,nuchal dystonia and dementia.a clinical report on eight cases of"heterogenous system degeneration[J].Trans Am Neurol Assoc,1963,88:25-29.
[20]Williams DR,Lees AJ.Progressive supranuclear palsy:clinicopathological concepts and diagnostic challenges[J].Lancet Neurol,2009,8(3):270-279.
[21]Koizumi R,Akagi A,Riku Y,et al.Clinicopathological features of progressive supranuclear palsy with asymmetrical atrophy of the superior cerebellar peduncle[J].Neuropathology,2023,43(3):233-243.
[22]Boxer AL,Yu JT,Golbe LI,et al.Advances in progressive supranuclear palsy:new diagnostic criteria, biomarkers, and therapeutic approaches[J].Lancet Neurol,2017,16(7):552-563.
[23]Santangelo G,Cuoco S,Pellecchia MT,et al.Comparative cognitive and neuropsychiatric profiles between Parkinsons disease, multiple system atrophy and progressive supranuclear palsy[J].J Neurol,2018,265(11):2602-2613.
[24]Gerstenecker A.The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration[J].Arch Clin Neuropsychol,2017,32(7):861-875.
[25]Pilotto A,Gazzina S,Benussi A,et al.Mild cognitive impairment and progression to dementia in progressive supranuclear palsy[J].Neurodegener Dis,2017,17(6):286-291.
[26]Albert ML,Feldman RG,Willis AL.The 'subcortical dementia' of progressive supranuclear palsy[J].J Neurol Neurosurg Psychiatry,1974,37(2):121-130.
[27]Zhao CS,Yan L,He WQ,et al.Distinct subcortical tau burden:the tau pallido-claustral ratio separates progressive supranuclear palsy and corticobasal degeneration[J].Brain Pathol,2022,32(2):e13030.
[28]Suthar N,Nebhinani N,Paul K.Neuropsychiatric symptoms as early manifestation of progressive supranuclear palsy[J].Indian J Psychol Med,2018,40(5):492-494.